News

Public · Published

United Therapeutics Corporation Stock 12‑Month Price Target Raised to $680.5, Implies 13% Upside

Estimates from 14 analysts raised United Therapeutics Corporation's average 12-month stock price target from $670.93 to $680.5. Based on the Nov. 3 closing price, the new target implies about 13% potential upside. The consensus rating remained Buy among 17 analysts: 14 Buys, two Holds and one Sell.

Published:

Updated:

What happened

Estimates from 14 analysts raised United Therapeutics Corporation’s average 12-month stock price target from $670.93 to $680.5. Based on the Nov. 3 closing price, the new target implies about 13% potential upside. The consensus rating remained Buy among 17 analysts: 14 Buys, two Holds and one Sell.

Confirmed

Global impact / market context

The higher average target signals a modest improvement in analysts’ expectations, but it is not a company forecast or a promise of returns. The broad range—from $368 to $850 per share—shows substantial disagreement, so the target offers limited certainty about future stock performance.

Analyst inference

The reported 13% upside is calculated from the Nov. 3 closing price, not a guaranteed return or a stated trading outcome. The estimates summarize analyst views; the supplied information gives no company results, business changes, or explanation for why the target rose.

Confirmed

What to watch

  1. Future analyst target changes could show whether the increase from $670.93 to $680.5 is sustained or reversed, while the wide forecast range highlights differing views. Analyst inference
  2. The article reports 14 Buys, two Holds and one Sell among 17 covering analysts; later rating changes would alter that stated consensus. Confirmed
  3. Compare subsequent company disclosures with analyst estimates to see whether new information supports changes to expected revenue, costs, or investment spending; none is described here. Analyst inference

Evidence

  • Original source link unavailable